Highly aligned container-closure solutions for sterile injectables

Schott Kaisha and Vanrx Pharmasystems offer pre-validated pharma packaging

Highly aligned container-closure solutions for sterile injectables from Schott Kaisha and Vanrx Pharmasystems. Photo: Schott Kaisha

Schott Kaisha and Vanrx Pharmasystems are announcing compatibility between Schott Kaisha’s ready-to-use nested syringes, cartridges and stoppers, and Vanrx’s Aseptic Filling Workcells.

The two companies have worked together to confirm these containers and closures as product sets as part of the Matrix Alliance, an industry initiative of leading packaging and component suppliers which aims to providing pre-validated container-closure solutions to work on Vanrx’s robotic aseptic filling machines. The Alliance was created because next-generation drugs require highly aligned manufacturing processes and packaging solutions.

These product sets are fully commercially available and ready-to-use, with closure integrity performance results available from Schott Kaisha and Vanrx. Using these product sets, pharmaceutical companies have the assurance that the combination will function as a high-performance primary packaging system for sterile injectables. Additionally, all elements of the set have been proven for compatibility and machinability with Vanrx aseptic filling systems.

Companies can move drug products to market faster, by establishing flexible manufacturing operations using pre-sterilized, nested ready-to-use containers and closures in combination with Vanrx’s robotic aseptic filling systems. As of today, product set combinations are available in Schott Kaisha 1 mL long syringes with Schott Kaisha nested syringe stoppers in both 100 and 160 unit per nest configurations, and Schott Kaisha 3 mL cartridges with Schott Kaisha nested cartridge stoppers in a 100 unit per nest configuration. These products are certified to work with Vanrx’s SA25 Aseptic Filling Workcell.

Rishad Dadachanji, Schott Kaisha’s director said, “As ready-to-use solutions gain traction in the market, we are determined to create a large portfolio consisting of all standard sizes, commercially available to our customers. Apart from being able to offer only the packaging, Vanrx and Schott Kaisha have taken the initiative to have our components validated for compatibility and machinability with the Vanrx system. This pre-validated combination of a single machine and broad product portfolio allows us to provide tested and reliable solutions to our common customers, enabling them with the flexibility to fill multiple sizes and a variety of products with ease.”

Vanrx’s vice president of marketing, Greg Speakman said, “Vanrx and Schott Kaisha have seen how pharmaceutical companies are shifting toward building flexible manufacturing operations. Schott Kaisha and Vanrx are helping bring new products to market faster, benefiting the patient and our customers’ ability to respond to uncertain market conditions.”

Schott Kaisha is a leading manufacturer of tubular glass primary packaging in India having completed 25 years in this business. Schott and Kaisha established a 50:50 joint venture for primary packaging activities in India in 2008. With 2600 employees and 2.5 billion pieces per annum, Schott Kaisha produces ampoules, vials, glass refilled syringes and cartridges. Vanrx Pharmasystems makes technologically advanced sterile filling solutions for the pharmaceutical industry. Vanrx fill-finish machines use isolated robotics and machine vision to automate the packaging of injectable drugs into nested vials, syringes, or cartridges.

The impact, resilience, and growth of responsible packaging in a wide region are daily chronicled by Packaging South Asia.

A multi-channel B2B publication and digital platform such as Packaging South Asia is always aware of the prospect of new beginnings and renewal. Its 16-year-old print monthly, based in New Delhi, India has demonstrated its commitment to progress and growth. The Indian and Asian packaging industries have shown resilience in the face of ongoing challenges over the past three years.

As we present our publishing plan for 2023, India’s real GDP growth for the financial year ending 31 March 2023 will reach 6.3%. Packaging industry growth has exceeded GDP growth even when allowing for inflation in the past three years.

The capacity for flexible film manufacturing in India increased by 33% over the past three years. With orders in place, we expect another 33% capacity addition from 2023 to 2025. Capacities in monocartons, corrugation, aseptic liquid packaging, and labels have grown similarly. The numbers are positive for most of the economies in the region – our platform increasingly reaches and influences these.

Even given the disruptions of supply chains, raw material prices, and the challenge of responsible and sustainable packaging, packaging in all its creative forms and purposes has significant headroom to grow in India and Asia. Our context and coverage engulf the entire packaging supply chain – from concept to shelf and further – to waste collection and recycling. We target brand owners, product managers, raw material suppliers, packaging designers and converters, and recyclers.

In an admittedly fragmented and textured terrain, this is the right time to plan your participation and marketing support communication – in our impactful and highly targeted business platform. Tell us what you need. Speak and write to our editorial and advertising teams! For advertisement ads1@ippgroup.in , for editorial info@ippgroup.in and for subscriptions subscription@ippgroup.in

– Naresh Khanna

Subscribe Now


Please enter your comment!
Please enter your name here